Svetlana Nikic, Founder and Principal of Precision Oncology Consulting, shared Natera’s post on LinkedIn, adding:
“Congratulations Natera – everyone knows the amount of hard work behind this approval – the evidence developed with Japanese collaborators which was used to bring MRD testing closer to patients across the globe.”
Quoting Natera’s post:
“Another milestone in Japan.
Signatera just received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic in muscle-invasive bladder cancer (MIBC). This follows the PMDA’s approval of Signatera in colorectal cancer less than three months ago.
Both approvals are backed by rigorous clinical evidence and research. As we work toward launching Signatera in Japan, we remain focused on bringing more patients access to the personalized insights Signatera can provide.”
Read the full article.
Proceed to the video attached to Natera’s post.
You may also be interested in: The Viral Side of Bladder Cancer: BK Polyomavirus, HPV, and Urothelial Carcinoma
